Our Team
Scientific Developers
John butler- Founder, CEO
After John’s wife Stephanie was diagnosed with late-stage metastatic cancer, John decided to focus his life’s work on advancing cancer research through the development of cutting edge technologies focused on advancing cancer research. Over the last 10 years, he has immersed himself in the global oncology community and has fostered very close and personal relationships with various institutions including Stanford, Dana Farber Cancer Institute, University of Berlin, and many other groups worldwide. His strong background in advanced technology development for biotech applications along with many years in operations gives him the experience to take technologies from concept into manufacturing and to the customer. John and Co-Founder, Dr. Bidhan Chaudhuri, have worked together for over 10 years developing technologies for DNA sequencing and oncology applications and moving these products into manufacturing in high throughput environments. John has held many positions throughout his career including Director of Manufacturing and Process Development at Pacific Biosystems, Visiting Scholar with Dr. Ron Davis at The Stanford Genome Technology Center and most recently as the CEO of Quantumcyte Inc.
bidhan chaudhuri- Founder, cto
Bidhan’s background is in Engineering, with a Ph.D. in Material Science and MEMS. He has brought several products from concept to high volume manufacturing. His expertise includes optical components to semiconductor processors (while at Intel) to developing and transferring new solar processes for Hanwha–from R&D in the US to factories in China. More recently, he was engineering manager at Intel in charge of developing the new 3D RealSense technology and moving it into manufacturing.
katie konigsfeld- Research scientist
Katie graduated from UC San Diego with a degree in biology and went straight into industry, working for a J. Craig Venter Company, Synthetics Genomics Inc., on the EMRE algal biofuels project. There, she honed her micro and molecular biology skills while helping develop, and eventually lead, their in house productivity assay. Switching gears, she worked on various productivity and phenotypic screening assays and then optimization of SGI’s BioXP 3200 system protocols before joining the QuantumCyte team where she is the research scientist. Katie focuses on instrumentation and molecular biochemistry development as well as helping on the operational aspects of the company.
aaron arvey- bioinformatition consultant
Dr. Aaron Arvey started his PhD in Machine Learning at UCSD and finished it in Computational Genomics at Cornell Medical School. During his HHMI-sponsored Postdoc at Sloan Kettering, he discovered mechanisms of regulatory T cell immunosuppression, which led to novel target now in clinical trials. His work in pharma (including Gilead Sciences) focused on immunotherapy and viral cure, including HIV, HBV, and publishing on clinical candidate cures for Dengue, Yellow Fever, and MERS/SARS. As an independent machine learning and biotech consultant, he delivers high impact strategy through analysis of complex datasets, including multiple diagnostic products coming to- and on- market. He has published 25 peer-reviewed manuscripts, is a frequent speaker at international meetings, and is a Visiting Scientist at UCSF.
Business Team
bernadine lim-VP BUSINESS DEVELOPMENT AND INVESTOR RELATIONS
Bernadine first started in U.S. equity sales at Montgomery Securities, a small boutique San Francisco based investment bank with a strong focus in small biopharma stocks, IPOs and private placements. She also worked at America Securities of San Francisco, a small San Francisco based investment advisory to fund managers specializing in publicly traded life sciences companies whose products fill unmet medical needs. Bernadine has also worked at Citigroup Global (Smith Barney) Markets in Singapore and spearheaded Citigroup Smith Barney’s first U.S. Equity Sales team in Jakarta, Indonesia, which ultimately became #2 ranked firm for U.S. Equities in Indonesia by revenue. At these firms, she managed the U.S. equity portfolio of prominent South-East Asian family wealth offices and financial institutions. In addition, she also served as liaison between Asian government agencies and U.S. biotech startups, helping each find the source to move forward. Bernadine is fluent in Mandarin, Taiwanese and Teochew.
cameron barnard- product commercialization
Cameron has spent nearly 20 years in life sciences tools and medical technology markets. Most recently as a VP/GM at Agilent Technologies, he has spent his career focused on global product and services commercialization in small and large enterprises with leadership, research and technical roles including business management, sales and marketing. Cameron has a BS in Business Administration and Information systems from Hofstra , a Bachelor’s degree from Central Queensland University (Marketing and Technology) and an MBA.
Scientific Advisory Board
dr. ron davis
Ronald Wayne "Ron" Davis is Professor of Biochemistry & Genetics, and Director of the Stanford Genome Technology Center at Stanford University. Davis is a researcher in biotechnology and molecular genetics, particularly active in human and yeast genomics and the development of new technologies in genomics, with over 30 biotechnology patents. Davis was listed in The Atlantic as one of the greatest innovators currently working: "A substantial number of the major genetic advances of the past 20 years can be traced back to Davis in some way." Dr. Davis is the director of the Scientific Advisory Board at the Open Medicine Foundation, a non-profit 501(c)(3) organization, whose goal is to fund and initiate research into chronic complex diseases. Presently the foundation is invested in The End ME/CFS Project, which aims to fast-track research for a cure for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).